Logo image of RLMD

RELMADA THERAPEUTICS INC (RLMD) Stock Fundamental Analysis

NASDAQ:RLMD - Nasdaq - US75955J4022 - Common Stock - Currency: USD

0.2898  0 (-0.75%)

After market: 0.287 0 (-0.97%)

Fundamental Rating

2

Taking everything into account, RLMD scores 2 out of 10 in our fundamental rating. RLMD was compared to 197 industry peers in the Pharmaceuticals industry. The financial health of RLMD is average, but there are quite some concerns on its profitability. RLMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RLMD had negative earnings in the past year.
RLMD had a negative operating cash flow in the past year.
RLMD had negative earnings in each of the past 5 years.
RLMD had a negative operating cash flow in each of the past 5 years.
RLMD Yearly Net Income VS EBIT VS OCF VS FCFRLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

RLMD's Return On Assets of -174.56% is on the low side compared to the rest of the industry. RLMD is outperformed by 87.31% of its industry peers.
Looking at the Return On Equity, with a value of -225.15%, RLMD is doing worse than 71.57% of the companies in the same industry.
Industry RankSector Rank
ROA -174.56%
ROE -225.15%
ROIC N/A
ROA(3y)-126.18%
ROA(5y)-97.03%
ROE(3y)-150.91%
ROE(5y)-113.88%
ROIC(3y)N/A
ROIC(5y)N/A
RLMD Yearly ROA, ROE, ROICRLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

RLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLMD Yearly Profit, Operating, Gross MarginsRLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, RLMD has more shares outstanding
The number of shares outstanding for RLMD has been increased compared to 5 years ago.
There is no outstanding debt for RLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLMD Yearly Shares OutstandingRLMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
RLMD Yearly Total Debt VS Total AssetsRLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

RLMD has an Altman-Z score of -24.13. This is a bad value and indicates that RLMD is not financially healthy and even has some risk of bankruptcy.
RLMD's Altman-Z score of -24.13 is on the low side compared to the rest of the industry. RLMD is outperformed by 86.29% of its industry peers.
RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.13
ROIC/WACCN/A
WACCN/A
RLMD Yearly LT Debt VS Equity VS FCFRLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.45 indicates that RLMD has no problem at all paying its short term obligations.
RLMD has a Current ratio of 4.45. This is in the better half of the industry: RLMD outperforms 68.02% of its industry peers.
A Quick Ratio of 4.45 indicates that RLMD has no problem at all paying its short term obligations.
The Quick ratio of RLMD (4.45) is better than 70.05% of its industry peers.
Industry RankSector Rank
Current Ratio 4.45
Quick Ratio 4.45
RLMD Yearly Current Assets VS Current LiabilitesRLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.21% over the past year.
EPS 1Y (TTM)19.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.18% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.88%
EPS Next 2Y17.38%
EPS Next 3Y18.98%
EPS Next 5Y12.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RLMD Yearly Revenue VS EstimatesRLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2M 4M 6M 8M 10M
RLMD Yearly EPS VS EstimatesRLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLMD. In the last year negative earnings were reported.
Also next year RLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLMD Price Earnings VS Forward Price EarningsRLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLMD Per share dataRLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as RLMD's earnings are expected to grow with 18.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.38%
EPS Next 3Y18.98%

More info and screens

0

5. Dividend

5.1 Amount

RLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELMADA THERAPEUTICS INC

NASDAQ:RLMD (4/17/2025, 8:00:02 PM)

After market: 0.287 0 (-0.97%)

0.2898

0 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-07 2025-05-07
Inst Owners29.77%
Inst Owner Change0%
Ins Owners8.69%
Ins Owner Change-1.2%
Market Cap9.62M
Analysts47.5
Price Target0.88 (203.66%)
Short Float %4.59%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.43%
Min EPS beat(2)-10.12%
Max EPS beat(2)12.98%
EPS beat(4)3
Avg EPS beat(4)12.44%
Min EPS beat(4)-10.12%
Max EPS beat(4)30.01%
EPS beat(8)7
Avg EPS beat(8)10.55%
EPS beat(12)8
Avg EPS beat(12)6.74%
EPS beat(16)10
Avg EPS beat(16)2.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40.38%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.27
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS0
BVpS1.07
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -174.56%
ROE -225.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.18%
ROA(5y)-97.03%
ROE(3y)-150.91%
ROE(5y)-113.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.45
Quick Ratio 4.45
Altman-Z -24.13
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.19%
EPS Next Y55.88%
EPS Next 2Y17.38%
EPS Next 3Y18.98%
EPS Next 5Y12.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.19%
OCF growth 3YN/A
OCF growth 5YN/A